The initial sensitivity of melanomas with activating BRAF mutations to BRAF inhibitors can be overcome by several mechanisms, including the compensatory upregulation of the EGFR tyrosine kinase coupled with downmodulation of the MITF and SOX10 transcription factors16,20,24,41. The gene discussed is EGFR; the disease is melanoma.